Selected article for: "primary endpoint and study primary endpoint"
Author: Huijie Bian; Zhao-Hui Zheng; Ding Wei; Zheng Zhang; Wen-Zhen Kang; Chun-Qiu Hao; Ke Dong; Wen Kang; Jie-Lai Xia; Jin-Lin Miao; Rong-Hua Xie; Bin Wang; Xiu-Xuan Sun; Xiang-Min Yang; Peng Lin; Jie-Jie Geng; Ke Wang; Hong-Yong Cui; Kui Zhang; Xiao-Chun Chen; Hao Tang; Hong Du; Na Yao; Shuang-Shuang Liu; Lin-Na Liu; Zhe Zhang; Zhao-Wei Gao; Gang Nan; Qing-Yi Wang; Jian-Qi Lian; Zhi-Nan Chen; Ping Zhu
Title: Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial
  • Document date: 2020_3_24
    • ID: 6g34qwer_17
    Snippet: The primary study endpoint was the virological clearance (i.e. negative conservation rate and time to negative) using qRT-PCR in nasopharyngeal swabs samples. Secondary efficacy endpoints were assessment of time to recovery of vital sign (including body temperature, respiratory rate, and SPO2), chest radiographic improvement, rate of PaO2/FiO2 recovery, time (days) to discharge, and inflammation recovery (percentage of patient with normal CRP con.....
    Document: The primary study endpoint was the virological clearance (i.e. negative conservation rate and time to negative) using qRT-PCR in nasopharyngeal swabs samples. Secondary efficacy endpoints were assessment of time to recovery of vital sign (including body temperature, respiratory rate, and SPO2), chest radiographic improvement, rate of PaO2/FiO2 recovery, time (days) to discharge, and inflammation recovery (percentage of patient with normal CRP concentration).

    Search related documents:
    Co phrase search for related documents
    • body temperature and day time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • body temperature and inflammation recovery: 1
    • body temperature and nasopharyngeal swab sample: 1, 2, 3
    • body temperature and qrt PCR: 1
    • body temperature and respiratory rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
    • body temperature and swab sample: 1, 2, 3, 4, 5, 6
    • body temperature and time assessment: 1, 2, 3, 4, 5
    • body temperature and virological clearance: 1
    • body temperature and vital sign: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • chest radiographic improvement and crp concentration: 1
    • chest radiographic improvement and inflammation recovery: 1
    • chest radiographic improvement and radiographic improvement: 1, 2, 3, 4, 5
    • chest radiographic improvement and virological clearance: 1
    • crp concentration and day time: 1
    • crp concentration and normal crp concentration: 1, 2, 3, 4, 5
    • crp concentration and primary study endpoint: 1
    • crp concentration and radiographic improvement: 1
    • crp concentration and respiratory rate: 1, 2
    • crp concentration and study endpoint: 1